

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

NCT07202663

Status	RECRUITING
Phase	Phase 1
Sponsor	Basking Biosciences, Inc.
Enrollment	72 participants

Key Eligibility Criteria

Inclusion (5)

- years of age
- Ability to provide written consent
- Weight 50-100 kg with BMI 18-32 kg/m²
- Willingness to use contraceptives
- Negative results for alcohol and drugs of abuse

Exclusion (13)

- Pregnant or lactating females
 - Familial bleeding disorder or individual or family history of bleeding diathesis or coagulopathy
 - Females with active menstruation on day of dosing
 - Use of prescription medications known to affect platelet function
 - Use of NSAIDs, aspirin, anti-platelet or anti-coagulation therapy within 10 days of dosing
- ... and 8 more (see full listing online)

Locations (1 total)

Scintia Clinical Research Ltd, Randwick, New South Wales, Australia